Comparing the Cost Effectiveness of a Celiac Disease Panel to a Testing Cascade

Caleb Bazyler^1, and Kevin Breuel²

¹Department of Sport, Exercise, Recreation, and Kinesiology, East Tennessee State University, Johnson City, TN, USA

²Department of Obstetrics, and Gynecology, East Tennessee State University Clinical Laboratories, Quillen College of Medicine, Johnson City, TN, USA

Cite this paper:
Caleb Bazyler and Kevin Breuel. Comparing the Cost Effectiveness of a Celiac Disease Panel to a Testing Cascade. International Journal of Celiac Disease. 2018; 6(1):11-13. doi: 10.12691/ijcd-6-1-6

Abstract

Recent reductions in healthcare funding in the United States has pressured clinical laboratories to provide the same quality of diagnostic testing with fewer resources. Testing cascades have been developed to assist in the diagnosis of various illnesses, which use fewer tests and subsequently reduce costs. However, the cost effectiveness of a celiac disease (CD) testing cascade compared to a panel is currently unknown. Therefore, the purpose of this study was to determine if a CD testing cascade was equivalent to a panel in identifying patients deemed likely for CD, and to compare their cost effectiveness in a sample of symptomatic patients from Northeast Tennessee. A retrospective analysis using a CD testing cascade was performed on 933 outpatient samples referred to our laboratory from 2012 to 2017 with a request for a celiac disease serology panel. The seroprevalence of CD for the panel and the cascade were the same in this population (1.82%, 95% binomial confidence interval: 1.06% to 2.90%). The total cost of the CD cascade was 268% less than the cost of the panel resulting in a savings of $44,705, which translates to a savings of $47.92/patient. Based on these findings, we recommend utilization of the cascade to identify patients with likely CD. In the future, creative use of novel testing strategies can have significant contributions to healthcare reform and afford patients more cost-effective clinical diagnostic testing.

Keywords:
healthcare reform seroprevalence celiac disease cascade

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Rubio-Tapia, A.; Hill, I.D.; Kelly, C.P.; Calderwood, A.H.; Murray, J.A. “Acg clinical guidelines: Diagnosis and management of celiac disease.” Am J Gastroenterol, 108 (5), 656-676. 2013.
[2]	Lebwohl, B.; Rubio-Tapia, A.; Guandalini, S.; Newland, C.; Assiri, A. “Diagnosis of celiac disease.” Gastrointest Endosc Clin N Am, 22 (4), 661-677. 2012.
[3]	Fasano, A.; Berti, I.; Gerarduzzi, T.; Not, T.; Colletti, R.B.; Drago, S.; Elitsur, Y.; Green, P.H.; Guandalini, S.; Hill, I.D., et al. “Prevalence of celiac disease in at-risk and not-at-risk groups in the united states: A large multicenter study.” Arch Intern Med, 163 (3), 286-292. 2003.
[4]	Katz, K.D.; Rashtak, S.; Lahr, B.D.; Melton, L.J., 3rd; Krause, P.K.; Maggi, K.; Talley, N.J.; Murray, J.A. “Screening for celiac disease in a north american population: Sequential serology and gastrointestinal symptoms.” Am J Gastroenterol, 106 (7), 1333-1339. 2011.
[5]	Catassi, C.; Kryszak, D.; Bhatti, B.; Sturgeon, C.; Helzlsouer, K.; Clipp, S.L.; Gelfond, D.; Puppa, E.; Sferruzza, A.; Fasano, A. “Natural history of celiac disease autoimmunity in a usa cohort followed since 1974.” Ann Med, 42 (7), 530-538. 2010.
[6]	Lippi, G.; Bassi, A.; Bovo, C. “The future of laboratory medicine in the era of precision medicine.” J Lab Precis Med. 1 (7). 1-5. 2016.
[7]	Lippi, G.; Plebani, M. “Laboratory medicine does matter in science (and medicine)… yet many seem to ignore it.” Clin Chem Lab Med, 53 (11), 1655-1656. 2015.
[8]	Tang, H.; Huang, T.; Jing, J.; Shen, H.; Cui, W. “Effect of procalcitonin-guided treatment in patients with infections: A systematic review and meta-analysis.” Infection, 37 (6), 497-507. 2009.
[9]	Marks, D.; Wonderling, D.; Thorogood, M.; Lambert, H.; Humphries, S.E.; Neil, H.A. “Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia.” BMJ, 324 (7349), 1303. 2002.
[10]	Wilke, M.H.; Grube, R.F.; Bodmann, K.F. “The use of a standardized pct-algorithm reduces costs in intensive care in septic patients - a DRG-based simulation model.” Eur J Med Res, 16 (12), 543-548. 2011.
[11]	Snyder, M.R. “Unpublished mayo clinic data.” 2012.
[12]	Borrelli, E.P. “Trends in hospitalizations for celiac disease in the United States.” Int J Celiac Dis, 5 (4), 150-154. 2017.